Browse by category

Novo Nordisk and Septerna have announced an exclusive global collaboration and license agreement to discover, develop and commercialise...

The United Laboratories International Holdings Limited’s (TUL) wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd....

Novo Nordisk has announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor...

Variant Bio has announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic...

Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...

Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...

GE HealthCare and Novo Nordisk are collaborating to further advance the clinical and product development of peripheral focused ultrasound...

Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...

Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...

Denmark's Novo Nordisk, the world's leading insulin maker, has revealed it will buy US-based Dicerna Pharmaceuticals, a developer of RNA...